News Releases
-
Feb 18, 2021-- Conference Call Scheduled for 4:30 p.m. ET --
-
Feb 16, 2021Marketing campaign includes the brand's first-ever commercial spot introducing women to a birth control that puts them in control of their body, their sex life, and their pregnancy prevention.
-
Feb 4, 2021Collaboration will provide resources about Phexxi® contraceptive vaginal gel to oncologists, pharmacists and associated healthcare providers
-
Jan 12, 2021Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®
-
Dec 22, 2020Approximately 25 Million Adult Women Covered by Medicaid
-
Dec 17, 2020High Level of Interest from Clinical Sites Seeking to Participate in EVOGUARD Trial
-
Nov 9, 2020Launched Phexxi™ (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free Contraception
-
Oct 27, 2020-- Conference Call Scheduled for 5:00 p.m. ET --
-
Oct 26, 2020- Live moderated video webcast discussion with members of Evofem management and Key Opinion Leader Patty Cason, RN, MS, FNP-BC, on Thursday, October 29th at 2:00 p.m. ET -
-
Sep 14, 2020- Company plans to initiate Phase 3 STI trial by the end of 2020 -
-
Sep 8, 2020- A First-in-Class Vaginal pH Modulator Designed for Use "In-the-Moment" -
-
Aug 4, 2020- Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 -
-
Jul 23, 2020-- Conference Call Scheduled for 11:00 a.m. EDT --
-
Jul 1, 2020- On-Track for September Launch of Phexxi™, the First FDA-Approved, Non-Hormonal, On-Demand Prescription Contraceptive Gel -
-
May 22, 2020- A New Class of Female-Controlled Birth Control for Use In-The-Moment -
-
May 6, 2020- On-Track for Phexxi™ PDUFA Date: May 25, 2020 -
-
Apr 28, 2020-- Conference Call Scheduled for 11:00 a.m. ET --
-
Apr 27, 2020- Funding to Support the Company's Launch and Commercialization Plans for Phexxi™ -
-
Apr 24, 2020- Perfect Use Efficacy Up to 93.3%; Exploratory Findings Demonstrate Increased Sexual Satisfaction and Vaginal Lubrication; Company Provides Updated Safety Outcomes -
-
Mar 12, 2020-- U.S. Food and Drug Administration (FDA) Grants Conditional Approval for New Brand Name - Phexxi™ --
-
Mar 3, 2020-- Conference Call Scheduled for 11:00 a.m. EDT --
-
Feb 26, 2020- Distinguished Career at the U.S. Food and Drug Administration in CDER and the Office of Women's Health; Significant Industry and Regulatory Expertise -
-
Dec 18, 2019- Assigns PDUFA Goal Date of May 25, 2020 -
-
Dec 2, 2019- AMPREVENCE Study Met Primary and Secondary Endpoints - a 50% Relative Risk Reduction in Chlamydia Infection and a 78% Relative Risk Reduction in Gonorrhea Infection Compared to Placebo -
-
Nov 26, 2019- Submission Supported by Phase 3 AMPOWER Data -
-
Nov 14, 2019- San Diego Business Journal Recognizes the City's Top 15 Female Business Leaders -
-
Nov 6, 2019Company on Track for Amphora NDA Resubmission to the U.S. FDA
-
Oct 24, 2019-- Conference Call Scheduled for 11:00 a.m. EST --